Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Panighel, G., Ferrarese, I., Lupo, M
Current Research Status and Future Directions Where We Are Now (2026) Retatrutide is currently in Phase 3 clinical development under Eli Lilly's TRIUMPH program, which includes multiple trials: TRIUMPH-3 Obesity without type 2 diabetes Evaluating 12mg vs 9mg vs placebo in adults with BMI 30 or 27 with comorbidities TRIUMPH-4 Obesity with type 2 diabetes Testing efficacy and safety in patients with both conditions (preliminary: 28.7% weight loss) MASLD/NASH Trials Metabolic dysfunction-associated steatotic liver disease Leveraging glucagon's liver fat reduction effects Cardiovascular Outcomes Long-term CV safety and benefits Following precedent of STEP and SURMOUNT trials for GLP-1 drugs Timeline to FDA Approval 2023: Phase 2 results published (NEJM) 2024-2026: Phase 3 trials ongoing (TRIUMPH program) 2026-2027: Anticipated FDA submission (if trials successful) 2027-2028: Potential FDA approval and commercial launch What Researchers Are Watching The main questions Phase 3 needs to answer: Long-term efficacy: Does weight loss plateau or continue beyond 48 weeks
It also restrains the movement of glucose to enter the body cells
Both pills launched at $149 per month for self-pay patients, a fraction of the cost of injectable GLP-1s, which have typically run upwards of $1,000 per month
US$ 24.07
US$ 27.49
US$ 24.93
US$ 28.35
US$ 26.62
US$ 20.05
US$ 27.23
US$ 27.04
US$ 22.24
